RecruitingPhase 3NCT06239727
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Principal Investigator
- Jun MaSun Yat-sen University
- Intervention
- PD-1 blocking antibody(drug)
- Enrollment
- 593 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2030
Study locations (26)
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
- Dongguan People's Hospital, Dongguan, Guangdong, China
- The First People's Hospital of Foshan, Foshan, Guangdong, China
- Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
- The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
- Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
- Guangdong Nongken Central Hospital, Zhanjiang, Guangdong, China
- Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
- The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China
- Hubei Province Cancer Hosiptal, Wuhan, Hubei, China
- Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
- Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
- +11 more locations on ClinicalTrials.gov
Collaborators
Jiangsu Hengrui Pharmaceutical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06239727 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07584499Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsSun Yat-sen University
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGPHASE3NCT07459296Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCFirst Affiliated Hospital of Guangxi Medical University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu